Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash from Operations (2018 - 2025)

Inmune Bio's Cash from Operations history spans 8 years, with the latest figure at 5439000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 22.14% year-over-year to 5439000.0; the TTM value through Sep 2025 reached 30651000.0, down 19.04%, while the annual FY2024 figure was 33361000.0, 178.47% down from the prior year.
  • Cash from Operations for Q3 2025 was 5439000.0 at Inmune Bio, up from 7375000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1141000.0 in Q1 2023 and bottomed at 11013000.0 in Q4 2024.
  • The 5-year median for Cash from Operations is 5709000.0 (2021), against an average of 6114157.89.
  • The largest annual shift saw Cash from Operations surged 87.13% in 2023 before it plummeted 555.21% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 9780000.0 in 2021, then skyrocketed by 41.77% to 5695000.0 in 2022, then surged by 40.28% to 3401000.0 in 2023, then tumbled by 223.82% to 11013000.0 in 2024, then skyrocketed by 50.61% to 5439000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Cash from Operations are 5439000.0 (Q3 2025), 7375000.0 (Q2 2025), and 6824000.0 (Q1 2025).